Vanberra Signal
Free trial

Diagnoptics

Curated by Signal

Non-invasive device to assess cardiovascular and diabetes risk

Life Sciences Technologydiagnoptics.com

Overview

Diagnoptics develops non-invasive diagnostic devices that allow diagnosis and assessment of the risk of diabetes and its associated complications. The company's proprietary CE marked product "AGE Reader" allows detection of fluorescence of accumulated Advanced Glycation Endproducts (AGEs) in 12 seconds. The reader's light source illuminates the skin of the forearm and this incident light allows excitation of fluorescent molecules in the tissues that emit light of a different wavelength which is detected using a spectrometer. The major contribution in fluorescence comes from collagen linked AGEs. Another product "Diab-spot", allows AGE measurement and combines it with few patient's characteristics to calculate the diabetes risk. The patient answers these questions related to other well-known diabetes risk factors using a touch screen. Diagnoptics offers a non-invasive and immediate assessment of cardiovascular risk and risk of diabetes with the AGE Reader.

Key facts

Founded
2003
Headquarters
Groningen, Netherlands
Stage
Sign up to view
Industry
Life Sciences Technology

Business model

3 products and services
Sign up to view

More on Vanberra Signal

Members only
Business overviewCore metrics and financialsPeopleLeadership and key peopleSimilar companiesPeers and competitorsDeep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

  • Photonics Healthcare

    Provider of monitoring device for cellular oxygen levels

    Life Sciences TechnologyUtrecht, Netherlands

  • European Pharma Group

    Develops needle-free device for the administration of insulin

    Life Sciences TechnologyAmsterdam, Netherlands

  • iGene

    Mobile application offering health guidance based on genetic information

    Life Sciences TechnologyNijmegen, Netherlands

About Diagnoptics

What does Diagnoptics do?

Diagnoptics develops non-invasive diagnostic devices that allow diagnosis and assessment of the risk of diabetes and its associated complications.

Where is Diagnoptics headquartered?

Diagnoptics is headquartered in Groningen, Netherlands.

When was Diagnoptics founded?

Diagnoptics was founded in 2003.

Which sector is Diagnoptics in?

Diagnoptics operates in Life Sciences Technology.

Who are Diagnoptics's competitors?

Companies similar to Diagnoptics include Photonics Healthcare, European Pharma Group, and iGene.